ORI Capital

AffyImmune Therapeutics is a biopharmaceutical company specializing in affinity tuned Chimeric Antigen Receptor (“CAR”) T cell therapy in solid tumors. The Company’s proprietary technology may significantly improve the existing CAR-T cell therapy by extending the target of CAR-T therapies to solid tumors using a novel molecule and tuning down the affinity from picomolar to micromolar level to lower the on-target off-tumor toxicity.

Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. Cold Genesys acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.

Pillar Biosciences Inc. specializes in developing and manufacturing next-generation sequencing (NGS) assays and software tailored for NGS laboratories. The company employs its patent-pending Stem-Loop Inhibition-Mediated amplification (SLIMamp) technology, which allows for precise priming of overlapping target segments, ensuring high sensitivity and specificity in clinical samples. Pillar Biosciences also offers an integrated bioinformatics analysis tool known as PiVAT, which enhances data processing through an improved binary alignment file. Founded in 2014 and headquartered in Natick, Massachusetts, with an additional location in Shanghai, China, the company has introduced beta versions of its Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel for validation studies in cancer centers and clinical testing organizations across the United States and China.

Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies. Cold Genesys acquired the rights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial.

Enable Injections, LLC develops a disposable body-worn bolus injector to deliver high viscosity/volume payloads to the subcutaneous tissue. The company’s system uses standard vial, syringe, or cartridge container closure; and automatically mixes lyophilized solutions. Its drug delivery system’s transfer package automatically warms the drug, and enables user to insert the container into the system, place the injector on the skin, and press the central button, as well as know the progress of the delivery through its viewing window, and then dispose the device. It also offers partial or multi-vial/syringe transfer systems for filling its LVWIs. The company was founded in 2010 and is based in Cincinnati, Ohio.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. Operating in the United Kingdom, European Union, and the United States, Orchard employs an autologous ex vivo gene therapy approach to transform patients’ hematopoietic stem cells into gene-modified products for treatment through a single administration. Its portfolio includes Strimvelis, the first approved gene therapy for adenosine deaminase-severe combined immunodeficiency (ADA-SCID), along with several products in clinical development targeting metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has a robust preclinical pipeline addressing various mucopolysaccharidosis types. Orchard collaborates with leading institutions in gene therapy, enhancing its research capabilities and clinical programs. Founded in 2015, Orchard Therapeutics continues to demonstrate a commitment to transforming the lives of patients through its advanced therapies.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Arterys Inc. is a technology company specializing in medical imaging analytics, aiming to enhance patient care through innovative solutions. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a cloud-based, AI-powered platform that enables radiologists to visualize and quantify blood flow in the body. Its product lineup includes Cardio AI for cardiac imaging, Lung AI for lung analysis, Liver AI for liver diagnostics, and Chest/MSK AI for detecting various thoracic and musculoskeletal conditions. The platform is fully web-based and FDA-cleared, providing clinicians with tools for automatic and interactive reporting. Additionally, the Arterys PHI Service allows physicians to access patient data remotely, further supporting efficient medical practices.

Surefire Medical, located in Westminster, Colorado, was established in 2009 to innovate in the interventional radiology sector. The company specializes in a unique infusion system that facilitates the precise delivery of embolic agents via its advanced catheter design. This system features an expandable tip that collapses during forward flow to preserve blood flow and expands against the vessel wall during reverse flow to minimize reflux. This innovative design aims to significantly reduce damage to healthy tissue, enhancing the effectiveness and safety of interventional procedures.

Kymab Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of human monoclonal antibody therapeutics. Utilizing its proprietary Kymouse platform, Kymab captures the diversity of the human immune system's B lymphocyte component to generate biopharmaceuticals targeting both established and novel drug targets. The company's therapeutic focus spans immuno-oncology, immunology, and other opportunistic areas. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to enhance its research and development efforts. Founded in 2009, Kymab continues to advance its pipeline of monoclonal antibody candidates aimed at addressing significant medical needs.

Enable Injections, LLC develops a disposable body-worn bolus injector to deliver high viscosity/volume payloads to the subcutaneous tissue. The company’s system uses standard vial, syringe, or cartridge container closure; and automatically mixes lyophilized solutions. Its drug delivery system’s transfer package automatically warms the drug, and enables user to insert the container into the system, place the injector on the skin, and press the central button, as well as know the progress of the delivery through its viewing window, and then dispose the device. It also offers partial or multi-vial/syringe transfer systems for filling its LVWIs. The company was founded in 2010 and is based in Cincinnati, Ohio.

Enable Injections, LLC develops a disposable body-worn bolus injector to deliver high viscosity/volume payloads to the subcutaneous tissue. The company’s system uses standard vial, syringe, or cartridge container closure; and automatically mixes lyophilized solutions. Its drug delivery system’s transfer package automatically warms the drug, and enables user to insert the container into the system, place the injector on the skin, and press the central button, as well as know the progress of the delivery through its viewing window, and then dispose the device. It also offers partial or multi-vial/syringe transfer systems for filling its LVWIs. The company was founded in 2010 and is based in Cincinnati, Ohio.

Pillar Biosciences Inc. specializes in developing and manufacturing next-generation sequencing (NGS) assays and software tailored for NGS laboratories. The company employs its patent-pending Stem-Loop Inhibition-Mediated amplification (SLIMamp) technology, which allows for precise priming of overlapping target segments, ensuring high sensitivity and specificity in clinical samples. Pillar Biosciences also offers an integrated bioinformatics analysis tool known as PiVAT, which enhances data processing through an improved binary alignment file. Founded in 2014 and headquartered in Natick, Massachusetts, with an additional location in Shanghai, China, the company has introduced beta versions of its Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel for validation studies in cancer centers and clinical testing organizations across the United States and China.